Generics - Diabetes


Current filters:


Popular Filters

India’s Lupin launches insulin glargine analogue Basugine


Indian generic drugmaker Lupin has entered into a strategic distribution agreement with LG Life Sciences…

BasugineBiosimilarsDiabetesGenericsIndiaLantusLG Life SciencesLupinMarkets & MarketingPeptide hormonesRecombinant proteinsSanofi

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA

Actavis challenges AstraZeneca’s diabetes drug Onglyza patent in the USA


Generics major Actavis yesterday confirmed that it has filed an Abbreviated New Drug Application with…


Tentative FDA clearance for generic copy of Novo Nordisk diabetes product


US drugmaker Perrigo (Nasdaq: PRGO; TASE) says it has received tentative approval from the US Food &…

DiabetesGenericsNorth AmericaNovo NordiskPerrigoPrandinRegulation

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Negative US patent ruling for Novo Nordisk on Prandin


Denmark-based insulin giant Novo Nordisk (NOV: N) says that the US Court of Appeals for the Federal Circuit…

DiabetesGenericsLegalNovo NordiskPatentsPharmaceuticalPrandin

Brazil interested in investing $4.5 Billion in Ukraine, including pharma


Brazil has submitted to Ukrainian authorities $4.5 billion worth of investment proposals. "We want to…

DiabetesEuropeFinancialGenericsPharmaceuticalProductionSouth America

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa


More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa…

BiotechnologyDiabetesGenericsMarkets & MarketingNephrology and Hepatology

Most US and European physicians believe automatic substitution of biosimilars is a bad idea


Specialist physicians surveyed in the USA and Europe are generally opposed to pharmacy-level automatic…

BiotechnologyDiabetesEuropeGenericsMarkets & MarketingNorth America

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree


The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Watson sues US FDA regarding generic Actos approval delay


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says it has filed suit against the US Food and…

ActosDiabetesGenericsLegalNorth AmericaTakeda PharmaceuticalsWatson Pharmaceuticals



Back to top